Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Larotrectinib in Pediatric NTRK Fusion Tumors (SCOUT)
NCT02637687Phase 2Active, not recruiting
- Sponsor
- Bayer
- Start
- Dec 2015
- Primary completion
- Jul 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 21
01
Overview
Phase 2, open-label trial of larotrectinib in solid tumor, central nervous system tumor, infantile fibrosarcoma (IFS) and 2 more (6 arms), sponsored by Bayer. Primary endpoints: Dose Limiting Toxicities at 28 days, Treatment Emergent Adverse Events at 93 months and 1 more. Started Dec 2015; status: active, not recruiting.
02
Drugs
larotrectinib
03
Conditions
solid tumorcentral nervous system tumorinfantile fibrosarcoma (IFS)mesoblastic nephroma (CMN)Secretory breast carcinoma (SBC)
Beyond the preview
Go deeper on NCT02637687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02637687.